Insider Selling: Relypsa Director Sells 4,167 Shares of Stock (RLYP)
Relypsa (NASDAQ:RLYP) Director Klaus R. Dr Veitinger sold 4,167 shares of Relypsa stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $27.73, for a total value of $115,550.91. Following the completion of the sale, the director now directly owns 2,712 shares of the company’s stock, valued at approximately $75,204. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Relypsa (NASDAQ:RLYP) traded down 3.15% during mid-day trading on Tuesday, hitting $24.89. 240,814 shares of the company’s stock traded hands. Relypsa has a 52-week low of $11.55 and a 52-week high of $52.74. The stock has a 50-day moving average of $24.01 and a 200-day moving average of $28.52. The company’s market cap is $842.4 million.
Relypsa (NASDAQ:RLYP) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. On average, analysts predict that Relypsa will post $-2.50 earnings per share for the current fiscal year.
Separately, analysts at Stifel Nicolaus raised their price target on shares of Relypsa from $45.00 to $47.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $48.50.
Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.